Pfizer completes sale of consumer business

Share this article:
Pfizer said today that it has completed the sale of its consumer healthcare business to Johnson & Johnson for $16.6 billion. “The proceeds from this sale, combined with our strong operating cash flow, give us the flexibility to invest in the growth of our core pharmaceutical business,” said Pfizer CEO Jeffrey Kindler in a statement. The deal was announced last June and cleared the Federal Trade Commission last week after the two companies agreed to sell off several products to resolve concerns the acquisition would reduce competition in some product areas. As part of that agreement, J&J will sell the rights to Pfizer’s Zantac heartburn treatment to Boehringer Ingelheim for $510 million. Additionally, Chattem, of Chattanooga TN, is to pay $410 million for the US rights to five J&J and Pfizer brands including Act mouthwash, Balmex diaper rash ointment, anti-diarrhea drug Kaopectate, sleep-aid Unisom and anti-itch treatment Cortizone. Pfizer’s consumer healthcare division posted $3.9 billion in sales in 2005.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.